Literature DB >> 6271801

Genetic and hormonal characterization of cryptic 21-hydroxylase deficiency.

L S Levine, B Dupont, F Lorenzen, S Pang, M Pollack, S E Oberfield, B Kohn, A Lerner, E Cacciari, F Mantero, A Cassio, C Scaroni, G Chiumello, G F Rondanini, L Gargantini, G Giovannelli, R Virdis, E Bartolotta, C Migliori, C Pintor, L Tato, F Barboni, M I New.   

Abstract

Cryptic 21-hydroxylase deficiency has been previously described in asymptomatic family members of patients with classical congenital adrenal hyperplasia (CAH). These family members were detected by high baseline 17-hydroxyprogesterone levels found in the course of family studies. The hormonal responses to ACTH of the family members with cryptic 21-hydroxylase deficiency were determined and compared to the responses of patients with CAH, patients with acquired adrenal hyperplasia, family members predicted to be heterozygous for CAH, family members predicted to be unaffected, and the general population. The ACTH-stimulated levels of 17-hydroxyprogesterone and delta 4-androstenedione in the cryptic family members were elevated above the level of the general population or family members heterozygous for classical CAH, but below that of patients with CAH. The hormonal profile of patients with cryptic 21-hydroxylase deficiency is similar to that of patients with acquired adrenal hyperplasia. The response of family members heterozygous for the cryptic gene (21-OH CRYPTIC/21-OH NORMAL) was indistinguishable from that of family members heterozygous for the classical CAH gene (21-OH CAH/21-OH NORMAL). These studies support our previous proposal that patients with cryptic 21-hydroxylase deficiency are genetic compounds, having one gene for a severe enzyme deficiency and one gene for a mild 21-hydroxylase deficiency. Thus, the 21-hydroxylase genotype in cryptic 21-hydroxylase deficiency is 21-OH CAH/21-OH CRYPTIC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271801     DOI: 10.1210/jcem-53-6-1193

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Reversible male infertility in late onset congenital adrenal hyperplasia.

Authors:  A Augarten; R Weissenberg; C Pariente; J Sack
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

2.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

Review 3.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families.

Authors:  Radha Nandagopal; Ninet Sinaii; Nilo A Avila; Carol Van Ryzin; Wuyan Chen; Gabriela P Finkielstain; Sneha P Mehta; Nazli B McDonnell; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2011-03-28       Impact factor: 6.664

5.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Genetics and biochemical variability of variants of 21 hydroxylase deficiency.

Authors:  M T Gordon; D I Conway; D C Anderson; R Harris
Journal:  J Med Genet       Date:  1985-10       Impact factor: 6.318

7.  The immunological detection of a 21-OH deficiency mutation HLA supratype.

Authors:  M S Pollack; B Keenan; F T Christiansen; T J Cobain; R L Dawkins; G Clayton
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

Review 8.  Disorders of sex development (DSD): not only babies with ambiguous genitalia. A practical guide for surgeons.

Authors:  Irene Kearsey; John M Hutson
Journal:  Pediatr Surg Int       Date:  2016-12-18       Impact factor: 1.827

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.